We are live on ! Find out more
DMAAR

Drugs Made In America Acquisition Corp Rights
DMAAR

35 hedge funds and large institutions have $887K invested in Drugs Made In America Acquisition Corp Rights in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 10 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

9% more funds holding

Funds holding: 32 → 35 (+3)

40% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 10

71% less capital invested

Capital invested by funds: $3.07M → $887K (-$2.18M)

Holders
35
Holders Change
+3
Holders Change %
+9.38%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
10
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MC
Meteora Capital
Florida
+$19.1K
2
QL
Quarry LP
New York
+$15.8K
3
WAM
Wolverine Asset Management
Illinois
+$13.8K
4
BFM
Boothbay Fund Management
New York
+$13.3K
5
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
+$12.4K

Top Sellers

Rank Fund Capital Flow
1
HCI
Harraden Circle Investments
New York
-$281K
2
AC
Aristeia Capital
Connecticut
-$65.4K
3
HCM
Heights Capital Management
California
-$37K
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$33.1K
5
GCL
Glazer Capital LLC
New York
-$25.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
COPPSERS
26
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$7.05K +$12.4K +117,544 New
DAM
27
DLD Asset Management
New York
$6.14K – – –
Verition Fund Management
28
Verition Fund Management
Connecticut
$5.47K -$85 -800 -0.8%
PC
29
Periscope Capital
Ontario, Canada
$4.5K – – –
LPC
30
Lineage Point Capital
Florida
$3.02K +$5.29K +50,000 New
GF
31
Gabelli Funds
New York
$2.98K +$5.22K +49,300 New
GCIA
32
Gabelli & Co Investment Advisers
New York
$2.9K +$5.09K +48,100 New
RAM
33
Readystate Asset Management
Illinois
$2.75K – – –
BI
34
Bulldog Investors
New Jersey
$2.62K -$9.2K -86,900 -67%
SG
35
StoneX Group
New York
$2.54K +$4.46K +42,120 New
HCI
36
Harraden Circle Investments
New York
– -$281K -1,500,000 Closed
HCM
37
Heights Capital Management
California
– -$37K -234,109 Closed
SSA
38
Schonfeld Strategic Advisors
New York
– -$22K -117,480 Closed
1
2

DMAAR Hedge Fund Activity: Q1 2026 in Review

35 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Drugs Made In America Acquisition Corp Rights (DMAAR) for Q1 2026, worth a combined $887K — down 71% from $3.07M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new DMAAR positions and 3 closed out — a net gain of 3 holders — while 6 added to existing stakes and 10 trimmed.

The largest buyer was Meteora Capital, adding an estimated $19.1K. The largest seller was Harraden Circle Investments, exiting entirely with an estimated $281K sold.

  • 35 institutional investors held Drugs Made In America Acquisition Corp Rights (DMAAR) as of Q1 2026, up from 32 in Q4 2025.
  • Funds reported $887K of Drugs Made In America Acquisition Corp Rights stock for Q1 2026, down 71% quarter-over-quarter.
  • 6 funds opened new Drugs Made In America Acquisition Corp Rights positions in Q1 2026 and 3 closed out, a net change of +3 holders.
  • The largest Drugs Made In America Acquisition Corp Rights buyer in Q1 2026 was Meteora Capital, an estimated $19.1K added.
  • The largest Drugs Made In America Acquisition Corp Rights seller in Q1 2026 was Harraden Circle Investments, an estimated $281K sold.

Based on aggregated 13F filings for Q1 2026.